ArticleAntimicrobial agents and chemotherapy2018
Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease.
Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Guideline
- Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.The European respiratory journal · 2020Guideline
- Amikacin Liposome Inhalation Suspension forAnnals of the American Thoracic Society · 2021Trial
- Radiographic severity and treatment optimisation inERJ open research · 2026Article
- Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistantAntimicrobial agents and chemotherapy · 2026Article
- Recent advances in immunopathogenesis and clinical practice: mastering the challenge-managing of non-tuberculous mycobacteria.Frontiers in immunology · 2025Review
- Review
- Article
- Article
- Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for RefractoryInfection and drug resistance · 2022Article
- Subunit vaccine protects against a clinical isolate of Mycobacterium avium in wild type and immunocompromised mouse models.Scientific reports · 2021Article
- Efficacy estimation of a combination of triple antimicrobial agents against clinical isolates ofJAC-antimicrobial resistance · 2021Article
- Outcomes of Inhaled Amikacin and Clofazimine-Containing Regimens for Treatment of RefractoryJournal of clinical medicine · 2020Article
- Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases.The Indian journal of medical research · 2020Review
- Observational
- Top Questions in the Diagnosis and Treatment of PulmonaryOpen forum infectious diseases · 2019Article
- Amikacin exposure and susceptibility of macrolide-resistantERJ open research · 2019Article
- Treatment ofTuberculosis and respiratory diseases · 2019Review
- Nontuberculous Mycobacterial Lung Diseases Caused by Mixed Infection with Mycobacterium avium Complex and Mycobacterium abscessus Complex.Antimicrobial agents and chemotherapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although guidelines recommend amikacin (AMK) inhalation therapy for difficult-to-treat nontuberculous mycobacterial lung disease (NTM-LD), data are limited regarding the safety and clinical efficacy of this salvage therapy. We retrospectively evaluated the treatment outcomes of 77 patients with refractory NTM-LD caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.